The goal of the center is to use outbred rats to study the genetic basis of drug self-administration and related behavioral traits. More information is available at www.ratgenes.org.
Dr. Palmer is a co-Investigator on the newly awarded R01 titled “Genetic Modulators of Glaucoma”. The PI is Dr. Monika Jablonski (Department of Ophthalmology in the College of Medicine at the University of Tennessee Health Science Center). The grant will be funded by the National Eye Institute to study glaucoma-related traits in HS rats. Dr. Jablonski has been collaborating with NIDA center on a GWAS in outbred rats led by Dr. Palmer. This grant will fund the phenotyping of eyes obtained from the NIDA center. Phenotypes obtained by Dr. Jablonski will
A new R01 grant from the National Eye Institute was awarded to Drs. Monica Jablonski, Abraham Palmer, and several others. The grant is titled, “Genetic Modulators of Glaucoma.”
Dr. Monica Jablonski (Department of Ophthalmology at the University of Tennessee) received the grant to study glaucoma-related traits in HS rats. Dr. Jablonski has been collaborating with the P50 Center, and this grant will fund phenotyping of eye samples and GWAS for glaucoma-related traits.
A new U01 grant from the National Institute on Drug Abuse (NIDA) was awarded to Drs. Abraham Palmer, Dongjun Chung, Roberto Ciccocioppo, Gerard Thomas Hardiman, Peter Kalivas, and Leah Catherine Solberg Woods. The grant is titled “The Genetic Basis of Opioid Dependence Vulnerablility in a Rodent Model.”
Dr. Sandra Sanchez-Roige’s project, titled “CADM2, a cell adhesion molecule, and its association with risk and psychopathology,” was selected for funding by the Brain & Behavior Research Foundation.
The NARSAD Young Investigator Grant provides support for the most promising young scientists conducting neurobiological research. Two year awards are provided to enable promising investigators to either extend research fellowship training or begin careers as independent research faculty. See their website for more information.
Dr. Abraham Palmer was awarded an R01 grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for his project titled “A Novel Pharmacotherapy for Alcoholism: Evaluation of Reward, Aversion, Compulsivity, Withdrawal & Reinstatement.” This is a five year grant that starts July 5, 2018 and ends April 30, 2023. This grant will fund a project to study how and why inhibitors of the enzyme GLO1 decrease ethanol drinking in mice and to develop GLO1 inhibitors for use as a therapy for alcohol use disorder.
Dr. Abraham Palmer was awarded a High Impact Research Project Award from the California Tobacco Related-Disease Research Program (TRDRP) for his project titled “Genetic relationship between impulsivity and nicotine abuse.” This is a three year, $750,000 grant that starts July 1, 2018 and ends June 30, 2021. This grant will fund a large project to study the genetics of impulsivity and a variety of traits related to smoking and other forms of drug abuse.
A U01 grant from the National Institute on Drug Abuse (NIDA) was awarded to Dr. Robert Hitzemann, Dr. Suzanne Mitchell, and Dr. Abraham Palmer. The grant, titled “Identification of genetic features of delay discounting using a heterogeneous stock rat model,” will start on July 1, 2018 and will end April 30, 2023.
The NIH’s National Institute on Drug Abuse (NIDA) recently awarded the Scripps Research team two separate grants totaling $7.5 million. The five-year grants will allow the researchers, led by Dr. Olivier George, to combine next-generation sequencing with rodent behavioral screening in a genetically diverse, nonhuman animal model of drug addiction. They will also create shared tissue banks for other researchers to use in addiction-related studies.
Dr. George’s group will collaborate with the lab of Dr. Leah Catherine Solberg Woods at Wake Forest University, who will breed the rats, and the lab of Dr.